AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19549427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study 16442368 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 774
Study 16442368 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 774
Study 16442368 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 774
Study 16442368 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg and 20 mg
Number of subjects: 774
Study 15246213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenytoin
Number of subjects: 42
Study 15246213 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 11348664 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 (Env, Gag, and protease)
Number of subjects: 19
Study 11348664 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1433 (Env, Gag, protease, and CTL epitope‐rich regions of pol and nef)
Number of subjects: 19
Study 11348664 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1452 (equivalent to vCP1433 with additional immunomodulatory genes of vaccinia)
Number of subjects: 19
Study 11348664 — intervention group
Group type: COMPARATOR
Intervention: lacZ control
Number of subjects: 19
Study 8995988 — intervention group
Group type: EXPERIMENTAL
Intervention: Senning procedure patients
Number of subjects: 43
Study 8995988 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 43
Study 8277150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 60 mg daily
Number of subjects: 785
Study 3553385 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable dressings
Number of subjects: 0
Study 3553385 — intervention group
Group type: COMPARATOR
Intervention: Petroleum gauze dressings
Number of subjects: 0
Study 28937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.0 mA, n=15)
Number of subjects: 42
Study 28937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label tDCS (1.5 mA, n=15)
Number of subjects: 42
Study 28937310 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=12)
Number of subjects: 42
Study 27965502 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak
Number of subjects: 240
Study 27965502 — intervention group
Group type: COMPARATOR
Intervention: Control (non-Miswak)
Number of subjects: 240
Study 24599529 — intervention group
Group type: EXPERIMENTAL
Intervention: AS02V with 10 or 30 μg PhtD-dPly
Number of subjects: 167
Study 24599529 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum with 10 or 30 μg PhtD-dPly
Number of subjects: 167
Study 24599529 — intervention group
Group type: EXPERIMENTAL
Intervention: 8PCV with AS02V or alum
Number of subjects: 167
Study 24599529 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (23PPV)
Number of subjects: 167
Study 22103985 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training programme (3 times weekly, starting at 60% of average peak torque, increasing from 1 set to 10 sets over sessions)
Number of subjects: 0
Study 22103985 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-burned adults)
Number of subjects: 0
Study 20648214 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only (Group I)
Number of subjects: 70
Study 20648214 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic mixed with non-particulate betamethasone (Group II)
Number of subjects: 70
Study 18977178 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (640 microg/cm² [8% capsaicin])
Number of subjects: 402
Study 18977178 — intervention group
Group type: COMPARATOR
Intervention: Control patch (3.2 microg/cm² [0.04% capsaicin])
Number of subjects: 402
Study 17124437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (40 mg/ml, 0.7 ml; n=24)
Number of subjects: 45
Study 17124437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (4 mg/ml, 0.7 ml; n=21)
Number of subjects: 45
Study 12502972 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (60 +/- 5%) in oxygen
Number of subjects: 224
Study 12502972 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (end-tidal concentration, 0.5%) combined with nitrous oxide (60 +/- 5%)
Number of subjects: 224
Study 12208583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg twice a day)
Number of subjects: 1613
Study 12208583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1613
Study 12208583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 1613
Study 9686803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Ischaemic Arrest (IIA)
Number of subjects: 91
Study 9686803 — intervention group
Group type: COMPARATOR
Intervention: Single Clamp Technique (SCT)
Number of subjects: 91
Study 9420743 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl imaging
Number of subjects: 30
Study 9420743 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐Q12 imaging
Number of subjects: 30
Study 3246246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.2 mg over 10 min)
Number of subjects: 16
Study 3246246 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 31075730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilisations
Number of subjects: 40
Study 31075730 — intervention group
Group type: COMPARATOR
Intervention: Motionless placebo
Number of subjects: 40
Study 27259463 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF‐IPIS with [Na+] of 240 mmol L-1
Number of subjects: 0
Study 27259463 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF‐IPIS with [Na+] of 500 mmol L-1
Number of subjects: 0
Study 27259463 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF‐IPIS
Number of subjects: 0
Study 27259463 — intervention group
Group type: COMPARATOR
Intervention: HD
Number of subjects: 0
Study 27259463 — intervention group
Group type: COMPARATOR
Intervention: HDF
Number of subjects: 0
Study 25439558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐20‐30 training
Number of subjects: 160
Study 25439558 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 160
Study 23823040 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation of femoral neck fractures
Number of subjects: 76
Study 21606153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Bifidobacterium lactis DN‐173 010 (n = 79)
Number of subjects: 159
Study 21606153 — intervention group
Group type: COMPARATOR
Intervention: Control product (n = 80)
Number of subjects: 159
Study 19349322 — intervention group
Group type: EXPERIMENTAL
Intervention: Established group (sodium reduction, weight loss, increased physical activity)
Number of subjects: 810
Study 19349322 — intervention group
Group type: EXPERIMENTAL
Intervention: Established-plus-DASH group (established lifestyle recommendations + DASH diet)
Number of subjects: 810
Study 19349322 — intervention group
Group type: COMPARATOR
Intervention: Advice-only group
Number of subjects: 810
Study 16675238 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (VP group)
Number of subjects: 50
Study 16675238 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE group)
Number of subjects: 50
Study 14728641 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment from a geriatric home hospitalization service (GHHS)
Number of subjects: 120
Study 14728641 — intervention group
Group type: COMPARATOR
Intervention: General medical ward treatment (GMW)
Number of subjects: 120
Study 11527658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 22
Study 11527658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus folic acid (10 mg every other day)
Number of subjects: 22
Study 11527658 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate alone
Number of subjects: 22
Study 9233409 — intervention group
Group type: EXPERIMENTAL
Intervention: Microelectrode-guided GPi pallidotomy
Number of subjects: 0
Study 8381646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir for 14 to 21 days (for primary TI‐CMV disease)
Number of subjects: 619
Study 8381646 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with ganciclovir (for recurrent TI‐CMV disease)
Number of subjects: 619
Study 8381646 — intervention group
Group type: COMPARATOR
Intervention: Patients with TI‐CMV disease
Number of subjects: 619
Study 8381646 — intervention group
Group type: COMPARATOR
Intervention: Recurrent TI‐CMV disease
Number of subjects: 619
Study 2893240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 to 1.0 mg in anaesthesiology; 0.1 to 2.0 mg in intensive care)
Number of subjects: 0
Study 2893240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (single dose)
Number of subjects: 0
Study 2893240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (repeated low intravenous doses or infusion at 0.1 mg/hour)
Number of subjects: 0
Study 2893240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 31177714 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation treatment of individualized exercise program
Number of subjects: 80
Study 28712349 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 600
Study 28712349 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 600
Study 26310880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-contact, out-of-lab, computer conditions
Number of subjects: 255
Study 26310880 — intervention group
Group type: COMPARATOR
Intervention: High-contact, in-lab, paper-and-pencil conditions
Number of subjects: 255
Study 26310880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil-and-paper surveys
Number of subjects: 255
Study 26310880 — intervention group
Group type: COMPARATOR
Intervention: Computer conditions
Number of subjects: 255
Study 23230065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rehydration (n = 8)
Number of subjects: 18
Study 23230065 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rehydration (n = 10)
Number of subjects: 18
Study 23230065 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (rapid and slow rehydration)
Number of subjects: 18
Study 21596324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment (20 mg/day, n = 40)
Number of subjects: 80
Study 21596324 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 40)
Number of subjects: 80
Study 19707815 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol (FT)
Number of subjects: 96
Study 19707815 — intervention group
Group type: COMPARATOR
Intervention: Conventional care protocol (C)
Number of subjects: 96
Study 16982296 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 3300000
Study 16982296 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 3300000
Study 15472853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive bandage
Number of subjects: 63
Study 15472853 — intervention group
Group type: COMPARATOR
Intervention: Gauze with adhesive tape
Number of subjects: 63
Study 15472853 — intervention group
Group type: COMPARATOR
Intervention: Gauze with a semipermeable dressing
Number of subjects: 63
Study 10637238 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CAF: cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 231
Study 10637238 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (CAFTH: CAF plus tamoxifen and Halotestin)
Number of subjects: 231
Study 10637238 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (CAFTH)
Number of subjects: 231
Study 10637238 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CAF)
Number of subjects: 231
Study 9261456 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed film format
Number of subjects: 6
Study 9261456 — intervention group
Group type: COMPARATOR
Intervention: Computer monitor format
Number of subjects: 6
Study 9261456 — intervention group
Group type: COMPARATOR
Intervention: Standard film format
Number of subjects: 6
Study 9261456 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists
Number of subjects: 6
Study 8348875 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (100 mg)
Number of subjects: 41
Study 8348875 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution (control for withdrawal)
Number of subjects: 41
Study 3097961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemohormonotherapy
Number of subjects: 0
Study 3097961 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29215955 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (TAS-102), administered twice per day orally; 5 days on and 2 days off for 2 weeks, followed by 14 days off per cycle.
Number of subjects: 406
Study 29215955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 27681394 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐herbal mouth rinse, 15 ml twice a day
Number of subjects: 120
Study 27681394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse, 15 ml twice a day
Number of subjects: 120
Study 27681394 — intervention group
Group type: EXPERIMENTAL
Intervention: essential oil mouth rinse, 15 ml twice a day
Number of subjects: 120
Study 27681394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sodium fluoride mouth rinse, twice a day
Number of subjects: 120
Study 24131637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus triple therapy (TT) - daily tacrolimus (0.1 mg/kg divided dose), azathioprine (1 mg/kg), and prednisolone (20 mg)
Number of subjects: 103
Study 24131637 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus monotherapy (MT)
Number of subjects: 103
Study 23006660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (6 g twice a day for 4 weeks)
Number of subjects: 122
Study 23006660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 20946631 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV
Number of subjects: 78
Study 20946631 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-CMV
Number of subjects: 78
Study 20946631 — intervention group
Group type: COMPARATOR
Intervention: LP-CMV
Number of subjects: 78
Study 20946631 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 78
Study 20946631 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups and ventilatory modes
Number of subjects: 78
Study 17711155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 64
Study 17711155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Number of subjects: 64
Study 15006216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-run telephone self-management programme including six weekly mailings of OA health education modules, a relaxation audio-tape, and six weekly 45 min follow-up telephone sessions.
Number of subjects: 32
Study 15006216 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 32
Study 11557168 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg) administered on days 1, 3, and 5 (AAA)
Number of subjects: 59
Study 11557168 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (0.25 mg/kg) administered on day 5 after placebo on days 1 and 3 (PPA)
Number of subjects: 59
Study 11557168 — intervention group
Group type: COMPARATOR
Intervention: placebo administered on days 1, 3, and 5 (PPP)
Number of subjects: 59
Study 10436540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone together with dexamethasone (group A1)
Number of subjects: 28
Study 10436540 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone only (group A2)
Number of subjects: 28
Study 10436540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with permanent neurological morbidity (group C)
Number of subjects: 28
Study 10436540 — intervention group
Group type: COMPARATOR
Intervention: Healthy survivors (group D)
Number of subjects: 28
Study 7908800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diazepam (ED)
Number of subjects: 91
Study 7908800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (EP)
Number of subjects: 91
Study 3398515 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX) - 5 walk/jog sessions at 60% V̇O2max per week for 5 weeks
Number of subjects: 21
Study 3398515 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise group (NEX)
Number of subjects: 21
Study 3398515 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 21
Study 30825962 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent FSRT and alisertib (20 mg, 30 mg, 40 mg, and 50 mg BID)
Number of subjects: 17
Study 30825962 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent FSRT and alisertib
Number of subjects: 17
Study 30825962 — intervention group
Group type: COMPARATOR
Intervention: Concurrent FSRT and alisertib (50 mg cohort)
Number of subjects: 17
Study 30068766 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased soluble cytoplasmic Bcl-2 protein (sBcl-2) serum levels in patients with JDM
Number of subjects: 0
Study 30068766 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of Bcl-2 in CD3+, CD4+, and CD8+ T lymphocytes in patients with JDM
Number of subjects: 0
Study 30068766 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased expression of Fas in CD3+, CD4+, and CD8+ T lymphocytes in patients with JDM
Number of subjects: 0
Study 27716442 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right parietal lobe (n=15)
Number of subjects: 60
Study 27716442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left parietal lobe (n=15)
Number of subjects: 60
Study 27716442 — intervention group
Group type: COMPARATOR
Intervention: Sham group of anodal tDCS over the right parietal lobe (n=15)
Number of subjects: 60
Study 27716442 — intervention group
Group type: COMPARATOR
Intervention: Sham group of cathodal tDCS over the left parietal lobe (n=15)
Number of subjects: 60
Study 24706097 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making
Number of subjects: 1523
Study 24706097 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in provider
Number of subjects: 1523
Study 23130818 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected persons
Number of subjects: 3295
Study 23130818 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 uninfected persons
Number of subjects: 3295
Study 21051894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track (FT) program
Number of subjects: 67
Study 21051894 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 67
Study 21051894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional risk score (NRS) ≥ 3
Number of subjects: 67
Study 17434884 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose leuprolide injections (0.5 mg/day)
Number of subjects: 103
Study 17434884 — intervention group
Group type: COMPARATOR
Intervention: Single-dose leuprolide injection (1.88 mg)
Number of subjects: 103
Study 16313111 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnebia Root oil (AO)
Number of subjects: 0
Study 16313111 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gauze (Control)
Number of subjects: 0
Study 12202657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m² plus carboplatin AUC 6 (group A)
Number of subjects: 509
Study 12202657 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m² plus gemcitabine 1,000 mg/m² (group B)
Number of subjects: 509
Study 10487973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 1204
Study 10487973 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1204
Study 8942329 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (20-h infusion at 0.1 ml kg-1 h-1)
Number of subjects: 64
Study 8942329 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (10% as placebo, 20-h infusion at 0.1 ml kg-1 h-1)
Number of subjects: 64
Study 2017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with education to 'internal spontaneity', resulting in a 21% decrease in energy intake (p < 0.05) and increased fruit and nonstarchy vegetable intake.
Number of subjects: 32
Study 2017470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary treatment).
Number of subjects: 32
Study 7072618 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (49.67 mg tin daily)
Number of subjects: 8
Study 7072618 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.11 mg tin daily)
Number of subjects: 8
Study 31804343 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-end position (HEP)
Number of subjects: 34
Study 31804343 — intervention group
Group type: COMPARATOR
Intervention: Leg-end position (LEP)
Number of subjects: 34
Study 28713004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheters (HCs)
Number of subjects: 78
Study 28713004 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheters (UCs)
Number of subjects: 78
Study 26407242 — intervention group
Group type: EXPERIMENTAL
Intervention: Music training
Number of subjects: 46
Study 26407242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 23725348 — intervention group
Group type: EXPERIMENTAL
Intervention: 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, containing approximately 15 μg of Phl p 5)
Number of subjects: 289
Study 23725348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 23725348 — intervention group
Group type: EXPERIMENTAL
Intervention: 2800 BAU Timothy grass AIT
Number of subjects: 289
Study 21553292 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (5-fluorouracil, doxorubicin, cyclophosphamide) × 8 cycles
Number of subjects: 511
Study 21553292 — intervention group
Group type: COMPARATOR
Intervention: TFAC (FAC × 4 cycles plus paclitaxel × 4 cycles)
Number of subjects: 511
Study 21553292 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC after BCT
Number of subjects: 511